Werkgroep Cardiologische centra Nederland

ENDEAVOR (Recruiting)

to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ejection Fraction > 40%
Medicine
AZD4831
Population
Heart failure
Phase
III
Starting year
2022